[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100539833":3},{"organization":4,"armGroups":7,"interventions":29,"overallOfficials":11,"centralContacts":51,"locations":57,"responsibleParty":269,"collaborators":11,"id":271,"slug":272,"hasResults":273,"nctId":274,"briefTitle":275,"officialTitle":275,"acronym":11,"eligibilityCriteria":276,"healthyVolunteers":273,"sex":277,"minAge":278,"maxAge":279,"enrollmentInfo":280,"targetDuration":11,"studyType":283,"phases":284,"briefSummary":286,"conditions":287,"keywords":293,"overallStatus":60,"whyStopped":11,"lastUpdateSubmitDate":306,"lastUpdatePostDateStruct":307,"startDateStruct":310,"completionDateStruct":312,"leadSponsor":314,"locationsCount":315},{"fullName":5,"class":6},"Fate Therapeutics","INDUSTRY",[8,17,20,23,26],{"label":9,"type":10,"description":11,"interventionNames":12},"Regimen A (Single dose with AMP)","EXPERIMENTAL",null,[13,14,15,16],"Drug: FT819","Drug: Fludarabine","Drug: Cyclophosphamide","Drug: Bendamustine",{"label":18,"type":10,"description":11,"interventionNames":19},"Regimen B (Single-dose without AMP, with background therapy)",[13],{"label":21,"type":10,"description":11,"interventionNames":22},"Regimen C (Two-dose with AMP)",[13,14,15,16],{"label":24,"type":10,"description":11,"interventionNames":25},"Regimen D (Two-dose without AMP, with background therapy)",[13],{"label":27,"type":10,"description":11,"interventionNames":28},"Regimen B1 (Single-dose without AMP, background therapy temporarily suspended)",[13],[30,35,41,47],{"type":31,"name":32,"description":33,"armGroupLabels":34,"otherNames":11},"DRUG","FT819","FT819 will be administered as intravenous (IV) infusion at planned dose levels.",[9,18,27,21,24],{"type":31,"name":36,"description":37,"armGroupLabels":38,"otherNames":39},"Fludarabine","Fludarabine will be administered as an IV infusion at planned dose levels.",[9,21],[40],"FLUDARA",{"type":31,"name":42,"description":43,"armGroupLabels":44,"otherNames":45},"Cyclophosphamide","Cyclophosphamide will be administered as an IV infusion at planned dose levels.",[9,21],[46],"CYTOXAN",{"type":31,"name":48,"description":49,"armGroupLabels":50,"otherNames":11},"Bendamustine","Bendamustine will be administered as an IV infusion at planned dose levels.",[9,21],[52],{"name":53,"role":54,"phone":55,"phoneExt":11,"email":56},"Fate Clinical Trials","CONTACT","858-875-1800","clinicaltrials@fatetherapeutics.com",[58,72,81,90,99,108,118,127,137,147,157,166,176,186,196,206,216,227,239,251,260],{"facility":59,"status":60,"city":61,"state":62,"zip":63,"country":64,"countryCode":65,"cosmosGeoPoint":66,"geoPoint":71,"contacts":11},"Wallace Rheumatic Center","RECRUITING","Beverly Hills","California","90210","United States","US",{"type":67,"coordinates":68},"Point",[69,70],-118.40036,34.07362,{"lat":70,"lon":69},{"facility":73,"status":60,"city":74,"state":62,"zip":75,"country":64,"countryCode":65,"cosmosGeoPoint":76,"geoPoint":80,"contacts":11},"Providence Medical Foundation","Fullerton","92835",{"type":67,"coordinates":77},[78,79],-117.92534,33.87029,{"lat":79,"lon":78},{"facility":82,"status":60,"city":83,"state":62,"zip":84,"country":64,"countryCode":65,"cosmosGeoPoint":85,"geoPoint":89,"contacts":11},"University of California Irvine","Irvine","92868",{"type":67,"coordinates":86},[87,88],-117.82311,33.66946,{"lat":88,"lon":87},{"facility":91,"status":60,"city":92,"state":62,"zip":93,"country":64,"countryCode":65,"cosmosGeoPoint":94,"geoPoint":98,"contacts":11},"Children's Hospital Los Angeles Division Of Rheumatology","Los Angeles","90027",{"type":67,"coordinates":95},[96,97],-118.24368,34.05223,{"lat":97,"lon":96},{"facility":100,"status":60,"city":101,"state":62,"zip":102,"country":64,"countryCode":65,"cosmosGeoPoint":103,"geoPoint":107,"contacts":11},"University of California San Francisco","San Francisco","94110",{"type":67,"coordinates":104},[105,106],-122.41942,37.77493,{"lat":106,"lon":105},{"facility":109,"status":60,"city":110,"state":111,"zip":112,"country":64,"countryCode":65,"cosmosGeoPoint":113,"geoPoint":117,"contacts":11},"University of Florida","Gainesville","Florida","32610",{"type":67,"coordinates":114},[115,116],-82.32483,29.65163,{"lat":116,"lon":115},{"facility":119,"status":60,"city":120,"state":111,"zip":121,"country":64,"countryCode":65,"cosmosGeoPoint":122,"geoPoint":126,"contacts":11},"Nicklaus Children's Hospital","Miami","33155",{"type":67,"coordinates":123},[124,125],-80.19366,25.77427,{"lat":125,"lon":124},{"facility":128,"status":60,"city":129,"state":130,"zip":131,"country":64,"countryCode":65,"cosmosGeoPoint":132,"geoPoint":136,"contacts":11},"University of Louisville","Louisville","Kentucky","40202",{"type":67,"coordinates":133},[134,135],-85.75941,38.25424,{"lat":135,"lon":134},{"facility":138,"status":60,"city":139,"state":140,"zip":141,"country":64,"countryCode":65,"cosmosGeoPoint":142,"geoPoint":146,"contacts":11},"University of Minnesota Medical School","Minneapolis","Minnesota","55455",{"type":67,"coordinates":143},[144,145],-93.26384,44.97997,{"lat":145,"lon":144},{"facility":148,"status":60,"city":149,"state":150,"zip":151,"country":64,"countryCode":65,"cosmosGeoPoint":152,"geoPoint":156,"contacts":11},"University of Nebraska Medical Center","Omaha","Nebraska","68198",{"type":67,"coordinates":153},[154,155],-95.94043,41.25626,{"lat":155,"lon":154},{"facility":158,"status":60,"city":159,"state":159,"zip":160,"country":64,"countryCode":65,"cosmosGeoPoint":161,"geoPoint":165,"contacts":11},"Montefiore Medical Center","New York","10467",{"type":67,"coordinates":162},[163,164],-74.00597,40.71427,{"lat":164,"lon":163},{"facility":167,"status":60,"city":168,"state":169,"zip":170,"country":64,"countryCode":65,"cosmosGeoPoint":171,"geoPoint":175,"contacts":11},"Duke University Health System","Durham","North Carolina","27705",{"type":67,"coordinates":172},[173,174],-78.89862,35.99403,{"lat":174,"lon":173},{"facility":177,"status":60,"city":178,"state":179,"zip":180,"country":64,"countryCode":65,"cosmosGeoPoint":181,"geoPoint":185,"contacts":11},"MetroHealth","Cleveland","Ohio","44109",{"type":67,"coordinates":182},[183,184],-81.69541,41.4995,{"lat":184,"lon":183},{"facility":187,"status":60,"city":188,"state":189,"zip":190,"country":64,"countryCode":65,"cosmosGeoPoint":191,"geoPoint":195,"contacts":11},"University of Oklahoma","Oklahoma City","Oklahoma","73019",{"type":67,"coordinates":192},[193,194],-97.51643,35.46756,{"lat":194,"lon":193},{"facility":197,"status":60,"city":198,"state":199,"zip":200,"country":64,"countryCode":65,"cosmosGeoPoint":201,"geoPoint":205,"contacts":11},"Jefferson Einstein Hospital Philadelphia","Philadelphia","Pennsylvania","19141",{"type":67,"coordinates":202},[203,204],-75.16362,39.95238,{"lat":204,"lon":203},{"facility":207,"status":60,"city":208,"state":209,"zip":210,"country":64,"countryCode":65,"cosmosGeoPoint":211,"geoPoint":215,"contacts":11},"Regional One Health","Memphis","Tennessee","38103",{"type":67,"coordinates":212},[213,214],-90.04898,35.14953,{"lat":214,"lon":213},{"facility":217,"status":60,"city":218,"state":11,"zip":219,"country":220,"countryCode":221,"cosmosGeoPoint":222,"geoPoint":226,"contacts":11},"Hôpital La Pitié Salpêtrière","Paris","75013","France","FR",{"type":67,"coordinates":223},[224,225],2.3488,48.85341,{"lat":225,"lon":224},{"facility":228,"status":60,"city":229,"state":230,"zip":231,"country":232,"countryCode":233,"cosmosGeoPoint":234,"geoPoint":238,"contacts":11},"Uppsala University","Uppsala","Uppland","752 37","Sweden","SE",{"type":67,"coordinates":235},[236,237],17.63889,59.85882,{"lat":237,"lon":236},{"facility":240,"status":60,"city":241,"state":242,"zip":243,"country":244,"countryCode":245,"cosmosGeoPoint":246,"geoPoint":250,"contacts":11},"Manchester University NHS Foundation Trust","Manchester","Greater Manchester","M139WL","United Kingdom","UK",{"type":67,"coordinates":247},[248,249],-2.23743,53.48095,{"lat":249,"lon":248},{"facility":252,"status":60,"city":253,"state":11,"zip":254,"country":244,"countryCode":245,"cosmosGeoPoint":255,"geoPoint":259,"contacts":11},"Cambridge University Hospitals NHS Foundation Trust","Cambridge","CB2 0QQ",{"type":67,"coordinates":256},[257,258],0.11667,52.2,{"lat":258,"lon":257},{"facility":261,"status":60,"city":262,"state":11,"zip":263,"country":244,"countryCode":245,"cosmosGeoPoint":264,"geoPoint":268,"contacts":11},"University College of London Hospitals NHS Trust (UCLH)","London","NW1 2PQ",{"type":67,"coordinates":265},[266,267],-0.12574,51.50853,{"lat":267,"lon":266},{"type":270,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100539833","phase-1-a-phase-1-study-of-ft819-in-b-cell-mediated-autoimmune-disease-100539833",false,"NCT06308978","A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease","Key Inclusion Criteria:\n\n* Age: 12 to 70 years old.\n* Diagnosis: Must have active B-cell mediated autoimmune disease (SLE, AAV, IIM, or SSc) confirmed by standard criteria.\n* Disease Severity: Moderate to severe, requiring at least two prior treatments that were ineffective.\n* Health Status: Adequate organ function to tolerate treatment.\n* Consent: Able to provide informed consent or assent\u002Fobtain parental consent and comply with study procedures.\n\nKey Exclusion Criteria:\n\n* Pregnancy\u002FBreastfeeding: Women must not be pregnant or nursing.\n* Severe Organ Dysfunction: Significant heart, lung, liver, or kidney impairment.\n* Active Infections: No recent or ongoing serious infections.\n* Recent Cancer or Prior Cell Therapy: No active\u002Frecent malignancies, prior CAR T-cell therapy, or organ transplant.\n* Allergies: No known allergies to study treatments.\n* Weight Restriction: Must weigh at least 50 kg (110 lbs).","ALL","12 Years","70 Years",{"count":281,"type":282},244,"ESTIMATED","INTERVENTIONAL",[285],"PHASE1","This is a phase 1 study designed to evaluate the safety, pharmacokinetics (PK), and anti-B-cell activity of FT819 following treatment with or without auxiliary medicinal product (AMP) in participants with moderate-to-severe active systemic lupus erythematosus (SLE) with or without nephritis, antineutrophilic cytoplasmic antibody (ANCA)-associated vasculitis (AAV), idiopathic inflammatory myositis (IIM), and systemic sclerosis (SSc). The study will consist of a dose-escalation stage, followed by an expansion stage to further evaluate the safety and activity of FT819.",[288,289,290,291,292],"Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV)","Idiopathic Inflammatory Myositis (IIM)","Systemic Sclerosis (SSc)","Systemic Lupus Erythematosus (SLE)","Lupus Nephritis",[32,5,294,295,296,297,298,299,300,301,302,303,304,305,292],"Idiopathic inflammatory myositis (IIM)","Systemic lupus erythematosus (SLE)","Systemic sclerosis (SSc)","Antineutrophilic cytoplasmic antibody (ANCA)-associated vasculitis (AAV)","Allogeneic CAR-T","CD19-Targeted Therapy","Cell Therapy for Autoimmune Diseases","B-Cell Depletion in Autoimmune Disease","Phase 1 Clinical Trial","Allogeneic CAR cells","Autoimmune Diseases","A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Diseases","2026-05-19",{"date":308,"type":309},"2026-05-22","ACTUAL",{"date":311,"type":309},"2024-03-28",{"date":313,"type":282},"2042-09-30",{"name":5,"class":6},21]